FDA Grants Orphan Drug Status to INN-108 as an Ulcerative Colitis Therapy for Children

FDA Grants Orphan Drug Status to INN-108 as an Ulcerative Colitis Therapy for Children
The U.S. Food and Drug Administration has granted orphan drug status to INN-108 as a treatment for children with ulcerative colitis, its maker, Innovate Biopharmaceuticals, announced in a press release. Regulators grant orphan drug designation to treatments that preliminary research indicates are better than current therapies, particularly for diseases with high unmet medical needs. With orphan status, FDA approval of the drug

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *